Clinical Trials on Bladder Cancer Stage

Total 57376 results

University of Southern California
National Cancer Institute (NCI)

Terminated

MDSC Clinical Assay in Finding and Monitoring Cancer Cells in Blood and Urine Samples From Patients With or Without Localized or Metastatic Bladder Cancer

Stage III Bladder Cancer | No Evidence of Disease | Stage II Bladder Cancer | Stage IVA Bladder Cancer | Stage IVB Bladder Cancer

United States
National Cancer Institute (NCI)

Completed

Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer

Stage III Bladder Cancer | Stage I Bladder Cancer | Stage II Bladder Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute

Completed

Addressing Barriers to Palliative Care Use in Bladder Cancer

Muscle-Invasive Bladder Carcinoma | Bladder Cancer Stage II | Bladder Cancer Stage III | Bladder Cancer Stage IV

United States
University of Washington
National Cancer Institute (NCI)

Completed

Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer

Stage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Bladder Carcinoma | Stage II Bladder Cancer

United States
National Cancer Institute (NCI)

Terminated

Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy

Stage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Bladder Carcinoma | Bladder Adenocarcinoma | Bladder Squamous Cell Carcinoma | Bladder Urothelial Carcinoma | Stage I Bladder Cancer | Stage II Bladder Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical Cystectomy

Stage III Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8 | Stage IIIA Bladder Cancer AJCC v8 | Stage IIIB Bladder Cancer AJCC v8 | Stage II Bladder Cancer AJCC v8

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Urinary Diversion During Robotic Assisted Radical Cystectomy in Patients With Bladder Cancer

Recurrent Bladder Cancer | Urinary Complications | Stage 0 Bladder Cancer | Stage I Bladder Cancer | Stage II Bladder Cancer
Mayo Clinic
National Cancer Institute (NCI)

Completed

Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer

Stage III Bladder Cancer AJCC v8 | Stage III Renal Pelvis Cancer AJCC v8 | Stage III Ureter Cancer AJCC v8 | Stage III Urethral Cancer AJCC v8 | Stage IIIA Bladder Cancer AJCC v8 | Stage IIIB Bladder Cancer AJCC v8 | Urethral Urothelial Carcinoma | Stage II Bladder Cancer AJCC v8 | Stage II Renal Pelvis... and other conditions

United States
Mayo Clinic

Recruiting

Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study

Stage 0a Bladder Cancer AJCC v8 | Stage 0is Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8 | Stage IIIA Bladder Cancer AJCC v8 | Stage II Bladder Cancer AJCC v8

United States
National Cancer Institute (NCI)

Completed

Gene Therapy in Treating Patients With Advanced Bladder Cancer

Recurrent Bladder Cancer | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Stage I Bladder Cancer | Stage II Bladder Cancer

United States
NRG Oncology
National Cancer Institute (NCI)

Terminated

Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer

Stage III Bladder Cancer | Stage IV Bladder Cancer

Canada, United States, Israel
Ankara Training and Research Hospital

Completed

Efficacy and Safety of Obturator Nerve Block During Transurethral Resection on Non-muscle Invasive Intermediate and High Risk Lateral Wall Bladder Tumours

Bladder Cancer Stage 0 | Bladder Cancer Stage I

Turkey
National Cancer Institute (NCI)
Radiation Therapy Oncology Group

Completed

Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer

Bladder Urothelial Carcinoma | Stage I Bladder Cancer AJCC v6 and v7 | Stage II Bladder Cancer AJCC v6 and v7 | Stage III Bladder Cancer AJCC v6 and v7

United States, Canada
IRCCS San Raffaele

Recruiting

Study on the Quality of Life and Pathological State in Patients Who Underwent Radical Cystectomy

Bladder Cancer | Muscle-Invasive Bladder Carcinoma | Radical Cystectomy | Urinary Diversion | Bladder Urothelial Carcinoma | Progression, Disease | Bladder Cancer Stage II | Bladder Cancer Stage IV | Muscle Invasive Bladder Urothelial Carcinoma | Neobladder | Bladder Cancer TNM Staging | Bladder Cancer Stage... and other conditions

Italy
National Cancer Institute (NCI)

Completed

Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer

Recurrent Bladder Carcinoma | Stage I Bladder Cancer AJCC v6 and v7 | Stage II Bladder Cancer AJCC v6 and v7 | Stage III Bladder Cancer AJCC v6 and v7

United States
University of Southern California
National Cancer Institute (NCI); National Institute for Biomedical Imaging...

Terminated

Ultrasound and Biomarker Tests in Predicting Cancer Aggressiveness in Tissue Samples of Patients With Bladder Cancer

Stage II Bladder Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma | Stage III Bladder Urothelial Carcinoma | Bladder Papillary Urothelial Carcinoma | Stage 0a Bladder Urothelial Carcinoma | Stage 0is Bladder Urothelial Carcinoma | Stage I Bladder Cancer With Carcinoma In Situ | Stage...

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Completed

Behavioral Dietary Intervention for the Improvement of Bladder Cancer Survivorship

Stage 0a Bladder Cancer AJCC v8 | Stage 0is Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8

United States
Roswell Park Cancer Institute
Johns Hopkins University; National Cancer Institute (NCI)

Terminated

Broccoli Sprout Extract in Treating Patients With Transitional Cell Bladder Cancer Undergoing Surgery

Recurrent Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Stage 0 Bladder Cancer | Stage I Bladder Cancer | Stage II Bladder Cancer

United States
University of Southern California
National Cancer Institute (NCI)

Terminated

sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer

Stage III Renal Cell Cancer | Recurrent Bladder Carcinoma | Stage I Prostate Cancer | Stage III Prostate Cancer | Infiltrating Bladder Urothelial Carcinoma | Stage II Bladder Urothelial Carcinoma | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage I Renal Cell Cancer | Stage II Renal Cell Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer

Recurrent Bladder Urothelial Carcinoma | Recurrent Renal Pelvis Urothelial Carcinoma | Recurrent Ureter Urothelial Carcinoma | Recurrent Urethral Urothelial Carcinoma | Stage III Renal Pelvis Cancer AJCC v8 | Stage III Ureter Cancer AJCC v8 | Stage III Urethral Cancer AJCC v8 | Stage 0a Bladder Cancer... and other conditions

United States
Fox Chase Cancer Center

Terminated

Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer

Stage III Bladder Cancer | Distal Urethral Cancer | Proximal Urethral Cancer | Squamous Cell Carcinoma of the Bladder | Urethral Cancer Associated With Invasive Bladder Cancer | Stage II Bladder Cancer

United States
Jonsson Comprehensive Cancer Center
AstraZeneca

Active, not recruiting

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

Stage IV Bladder Cancer AJCC v8 | Stage IVA Bladder Cancer AJCC v8 | Stage IVB Bladder Cancer AJCC v8 | Bladder Urothelial Carcinoma

United States
University of Chicago
National Cancer Institute (NCI)

Terminated

Afatinib in Advanced Refractory Urothelial Cancer

Recurrent Bladder Cancer | Stage III Bladder Cancer | Stage IV Bladder Cancer | Ureter Cancer | Distal Urethral Cancer | Proximal Urethral Cancer | Recurrent Urethral Cancer | Stage III Urethral Cancer | Stage IV Urethral Cancer

United States
Mamta Parikh
National Cancer Institute (NCI)

Recruiting

PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer

Stage 0a Bladder Cancer AJCC v8 | Stage 0is Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8 | Recurrent Non-Muscle Invasive Bladder Carcinoma

United States
Ankara Etlik City Hospital

Completed

The Impact of Neoadjuvant Chemotherapy on Survival Outcomes in Patients With Variant Histologies Bladder Cancer Who Underwent Radical Cystectomy

Bladder Cancer | Bladder Cancer Stage I | Bladder Cancer Stage II

Turkey
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Bladder Urothelial Carcinoma In Situ | Stage 0a Bladder Cancer AJCC v8 | Stage 0is Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8 | Invasive Bladder Mixed Carcinoma

United States, Guam, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

Advanced Bladder Urothelial Carcinoma | Advanced Ureter Urothelial Carcinoma | Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Recurrent Bladder... and other conditions

United States
University of California, Davis
National Cancer Institute (NCI); IO Biotech

Recruiting

IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

Stage 0a Bladder Cancer AJCC v8 | Stage 0is Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8 | High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations

Recurrent Ovarian Carcinoma | Recurrent Head and Neck Carcinoma | Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer | Endometrial Carcinoma | Stage III Bladder Cancer | Cervical Squamous Cell Carcinoma | Stage IV Breast Cancer | Malignant Uterine Neoplasm | Recurrent Bladder Carcinoma | Recurrent... and other conditions

United States
University of Washington
Bladder Cancer Advocacy Network

Recruiting

A Home-Based Prehabilitation Exercise Intervention for Improving Physical Function in Patients Receiving Chemotherapy Before Radical Cystectomy, Get Moving Trial

Stage IIIA Bladder Cancer AJCC v8 | Muscle Invasive Bladder Carcinoma | Stage II Bladder Cancer AJCC v8

United States
Northwestern University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer

Recurrent Bladder Carcinoma | Stage I Bladder Cancer | Stage 0a Bladder Urothelial Carcinoma | Stage 0is Bladder Urothelial Carcinoma

United States
University of Southern California
National Cancer Institute (NCI); GlaxoSmithKline

Terminated

Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder

Recurrent Bladder Cancer | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder

United States
University of Washington
Gilead Sciences

Recruiting

Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer

Stage IIIA Bladder Cancer AJCC v8 | Muscle Invasive Bladder Carcinoma | Stage II Bladder Cancer AJCC v8

United States
University of Washington
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer

Stage IIIA Bladder Cancer AJCC v8 | Muscle Invasive Bladder Carcinoma | Stage II Bladder Cancer AJCC v8

United States
European Organisation for Research and Treatment...
National Cancer Institute (NCI); NCIC Clinical Trials Group; Institute of Cancer... and other collaborators

Completed

Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium

Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder
M.D. Anderson Cancer Center

Recruiting

Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression

Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Recurrent Bladder Urothelial Carcinoma | Recurrent Renal Pelvis Urothelial Carcinoma | Recurrent... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study

Advanced Bladder Urothelial Carcinoma | Advanced Ureter Urothelial Carcinoma | Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Stage III Bladder Cancer AJCC v8 | Stage III... and other conditions

United States, Canada
National Cancer Institute (NCI)

Withdrawn

Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial

Urothelial Carcinoma | Renal Pelvis and Ureter Urothelial Carcinoma | Bladder Carcinoma | Stage III Bladder Cancer AJCC v8 | Stage IVA Bladder Cancer AJCC v8 | Bladder Urothelial Carcinoma | Muscle Invasive Bladder Carcinoma | Stage II Bladder Cancer AJCC v8

Canada
National Cancer Institute (NCI)

Recruiting

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Stage IV Bladder Cancer AJCC v8 | Stage IV Renal Pelvis Cancer AJCC v8 | Stage IV Ureter Cancer... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer

Recurrent Bladder Urothelial Carcinoma | Bladder Urothelial Carcinoma In Situ | Stage 0a Bladder Cancer AJCC v8 | Stage 0is Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8 | Superficial Bladder Urothelial Carcinoma

United States
The University of Texas Health Science Center at...

Completed

Neoadjuvant Rapamycin in Patients Undergoing Radical Cystectomy

Invasive Bladder Cancer Stage II

United States
Emory University

Terminated

Adjuvant Radiation for High Risk Bladder Cancer

Bladder Cancer | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Squamous Cell Carcinoma of the Bladder

United States
National Cancer Institute (NCI)

Completed

Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Bladder Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Ureter Cancer | Recurrent Urethral... and other conditions

United States
Peking University

Withdrawn

PD-1 Knockout Engineered T Cells for Muscle-invasive Bladder Cancer

Invasive Bladder Cancer Stage IV

China
National Cancer Institute (NCI)

Active, not recruiting

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

Bladder Urothelial Carcinoma | Stage IIIA Bladder Cancer AJCC v8 | Muscle Invasive Bladder Carcinoma | Stage II Bladder Cancer AJCC v8

United States
M.D. Anderson Cancer Center

Recruiting

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Clinical Stage III Cutaneous Melanoma AJCC v8 and other conditions

United States
Barbara Ann Karmanos Cancer Institute

Completed

Ask Questions (ASQ):Implementation of a Communication Intervention

Stage IV Lung Cancer | Stage III Bladder Cancer | Stage IV Bladder Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage III Breast Cancer | Stage IV Colorectal Cancer | Stage IV Ovarian Cancer | Stage III Lung Cancer | Stage III Cervical Cancer and other conditions

United States
Yuanquan Yang
Gateway for Cancer Research

Not yet recruiting

Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy

Bladder Urothelial Carcinoma | Stage IIIA Bladder Cancer AJCC v8 | Muscle Invasive Bladder Carcinoma | Stage II Bladder Cancer AJCC v8

United States
Roswell Park Cancer Institute

Recruiting

An Education and Navigation Support Tool to Improve Participation in Care Coordination Among Patients With Locally Advanced, Metastatic and Unresectable Bladder Cancer and Their Caregivers

Stage III Bladder Cancer AJCC v8 | Stage IV Bladder Cancer AJCC v8 | Metastatic Bladder Carcinoma | Locally Advanced Bladder Carcinoma | Unresectable Bladder Carcinoma

United States
University of Southern California
National Cancer Institute (NCI)

Withdrawn

sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer

Recurrent Bladder Carcinoma | Bladder Cancer Stage 0 | Bladder Cancer Stage I

United States

Clinical Trials on Bladder Cancer Stage

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations